

### ZIKA VIRUS TESTING AND REPORT FORM



Acute Communicable Disease Control 313 N. Figueroa St., Rm. 212 Los Angeles, CA 90012 213-240-7941 (phone), 213-482-4856 (fax) publichealth.lacounty.gov/acd/

## FAILURE TO COMPLETE REQUIRED FIELDS WILL RESULT IN SPECIMEN REJECTION OR DELAYED TESTING

| REQUIRED SUBMITTER INFORMATION   |                                     |                           | Date of Request                         |  |
|--|-------------------------------------|---------------------------|---|--|
| Requesting Physician Name (Last, First)  |                                     |                           |   |  |
|  | Tability/Submitter Name and Address |                           |   |  |
|  |                                     |                           |   |  |
|  |                                     |                           |   |  |
| Requesting Physician Pager or Phone No.  | Facility Fax Number                 | Facility Phone Number     | Contact Person for Specimen(s)          |  |
|  |                                     |                           |   |  |
| Requesting Physician Email   |                                     |                           | Contact Person Phone                    |  |
|  |                                     |                           |   |  |
| REQUIRED EPIDEMIOLOGICAL INF   | FORMATION                           |                           |   |  |
| The patient:   |                                     | _                         |   |  |
|  |                                     |                           | Il appropriate HEALTH DEPARTMENT.       |  |
| 2. Has a history of travel to a Zika affe  |                                     |                           |   |  |
| If Yes, Country?   |                                     | of travel: From           | to                                      |  |
| 3. Is what gender?   Male Fema   |                                     |                           |   |  |
| If Female, Pregnant?   Yes   No  |                                     | -                         |   |  |
| Ultrasound screening evidence of   | · · ·                               |                           |   |  |
|  |                                     |                           | s w/in 14 days of his return?  Yes  No  |  |
|  |                                     |                           | ther testing form for symptomatic male. |  |
| 4. Has any of the following symptoms?   Yes No If Yes, Specify symptoms and Onset Date:                              |                                     |                           |   |  |
| ☐ Acute onset of fever (mea  |                                     |                           | *                                       |  |
| 5. Is a postpartum mother who has an   |                                     |                           | •                                       |  |
| 6. Has a Guillain-Barré Syndrome diag  |                                     | o If Yes, Specify Onset L | Date:                                   |  |
| REQUIRED ELIGIBILITY SCREEN F  |                                     |                           |   |  |
| Using the Epidemiological Information section above, check ☑ which category the travelers fits in:                   |                                     |                           |   |  |
| ☐ Symptomatic Pregnant Traveler ☐ Onset of symptoms within 14 days of return OR ☐ Onset during travel                |                                     |                           |   |  |
| Asymptomatic Pregnant Traveler - Within 12 weeks after return from travel  |                                     |                           |   |  |
| ☐ Pregnant Traveler – regardless of symptoms   |                                     |                           |   |  |
| ☐ Ultrasound screening evidence of microcephaly and/or calcifications in a fetus OR ☐ Fetal loss                     |                                     |                           |   |  |
| ☐ Infant of a Recently Pregnant Traveler - Evidence of microcephaly in an infant                                     |                                     |                           |   |  |
| Provide Mother's Name and Mother's Date of Birth   |                                     |                           |   |  |
| ☐ Infant with no apparent defect AND the mother has laboratory evidence of Zika virus infection (See instructions.)  |                                     |                           |   |  |
| $\square$ Symptomatic pregnant woman with NO travel history AND had unprotected sex with a symptomatic male traveler |                                     |                           |   |  |
| ☐ Symptomatic Non-Pregnant Traveler (Male or Female) - Onset of symptoms within 14 days of return                    |                                     |                           |   |  |
| ☐ Traveler with a Guillain-Barré Syndrome diagnosis  |                                     |                           |   |  |
| ☐ Patient does not fit into any of the above categories.   |                                     |                           |   |  |
| Contact Acute Communicable Disease Control at 213-240-7941 for consultation.   |                                     |                           |   |  |
| Patient Name (Last, First, Middle Initial)   |                                     |                           | Date of Birth (mm/dd/yyyy)              |  |
|  |                                     |                           |   |  |



California Certified Public Health Laboratory #335637 CLIA #05D1066369

# COUNTY OF LOS ANGELES DEPARTMENT OF PUBLIC HEALTH PUBLIC HEALTH LABORATORIES

12750 Erickson Avenue Downey, CA 90242 Phone 562-658-1330/1300 Fax 562-401-5999 PUBLIC HEALTH LAB USE ONLY

#### ZIKA TEST REQUISITION

THIS PART OF THE FORM MUST BE ACCOMPANIED BY PAGE 1
A SEPARATE TEST REQUEST MUST BE COMPLETED FOR EACH SPECIMEN TYPE

ALL FIELDS ON THIS PART OF THE FORM MUST BE COMPLETED
FAILURE TO COMPLETE ALL FIELDS WILL RESULT IN SPECIMEN REJECTION OR DELAY

| REQUIRED PATIENT INFORMATION  |                            |  |            |          |  |
|---|----------------------------|--|------------|----------|--|
| Patient Name (Last, First, Middle Initial)  | Date of Birth (mm/dd/yyyy) | Sex  |            |          |  |
|   |                            | ☐ Male ☐ Fen   | nale 🗌 Otl | ner      |  |
| Patient Address- Number, Street, Apt #  | City                       |  | State      | ZIP Code |  |
|   |                            |  |            |          |  |
| Patient Home Telephone Number   | Patient Work Telephone Nu  | mber Patient Cell Number                                 |            | I Number |  |
|   |                            |  |            |          |  |
| MRN/Patient ID  | Requesting Physician (Last | , First)   |            |          |  |
|   |                            |  |            |          |  |
| Previous Vaccination?   | Fever ☐ Japanese Equine E  | ncephalitis  |            |          |  |
| Previous Testing? Chikungunya  Pos Neg Pending Not done Dengue Pos Neg Pending Not done |                            |  |            |          |  |
| REQUIRED – Test(s) Requested  |                            | REQUIRED - Specimen Source                               |            |          |  |
|   |                            | Each specimen type requires a separate test request form |            |          |  |
| ☐ Arbovirus serology panel (serum, cord blood, or CSF)                                  |                            |  |            |          |  |
| Includes Zika, Chikungunya, and Dengue  | Serum                      |  |            |          |  |
|   | ☐ Urine                    |  |            |          |  |
| ☐ Arbovirus RT-PCR (serum, cord blood, urine, body fluids, a                            | Cord Blood                 |  |            |          |  |
| Includes Zika, Chikungunya, and Dengue  |                            | Amniotic Fluid   |            |          |  |
|   | Fetal tissue               |  |            |          |  |
| ☐ Immunohistochemistry (fixed tissue or paraffin block)                                 |                            | (specify type):  |            |          |  |
|   |                            | ☐ Placenta   |            |          |  |
| ☐ Histopathology (fixed tissue or paraffin block)                                       |                            | ☐ CSF (if collected for other purposes)                  |            |          |  |
|   |                            | REQUIRED   |            |          |  |
|   |                            | Date specimen co   | ollected:  |          |  |
|   |                            |  | Time:      |          |  |
|   |                            |  |            |          |  |



## INSTRUCTION FOR ZIKA TEST REQUESTS Guidance Date: June 23, 2016

Recommendations may be frequently updated. Ensure that you check DPH website frequently for updated guidance and instructions.

1. If a provider suspects a case of Zika virus and requires testing, the provider should obtain relevant patient clinical history including previous Dengue/Chikungunya/West Nile Virus, patient travel history, Japanese encephalitis virus/Yellow Fever/Tickborne Encephalitis vaccination history, and results of other relevant diagnostic tests if performed (ex. ultrasound imaging, TORCH serology panel, West Nile virus serology, Dengue serology, Chikungunya serology, etc.).

For an updated list of countries with Zika virus infection, visit the following websites: http://www.cdc.gov/zika/geo/active-countries.html

- Appropriate samples types and available tests are described in the tables below. In general, suspect acute
  Zika patients, should receive both serology and PCR testing. If ≤7 days from onset of symptoms, submit
  both urine and serum specimens. Asymptomatic patients with suspect Zika exposure should receive
  serology testing. Note, requests for serology and PCR requires separate specimens.
- 3. Provider downloads and completes the "Zika Virus Testing and Report" form from the Los Angeles County Department of Public Health website. Separate testing forms (both pages 1 and 2) must accompany each specimen type. See <a href="http://publichealth.lacounty.gov/acd/docs/ZikaInfoTestReq.pdf">http://publichealth.lacounty.gov/acd/docs/ZikaInfoTestReq.pdf</a>.
- 4. The "Required Information for Zika Virus Testing" form indicates required information and must contain the following:
  - (1) Facility/Submitter name, address, phone, and fax
  - (2) Requesting provider name (Last, First) and contact information to enable reporting of results.
  - (3) Patient name or unique patient identifier
  - (4) Patient sex
  - (5) Patient date of birth
  - (6) Test(s) to be performed
  - (7) Specimen source
  - (8) Date and time of specimen collection
- 5. Provider collects samples and sends to the Los Angeles County Public Health Laboratories.

If provider or patient is unable to obtain phlebotomy services, contact the Los Angeles Acute Communicable Disease Control Program for assistance, approval, and referral to a Los Angeles County Public Health Clinic.

- 6. Specimens must be labeled with the following information:
  - Patient name (Last, First)
  - Date of Birth
  - Collection Date and Collection Time

Samples must be sent to the Los Angeles County Public Health Laboratories as soon as possible and within 24 hours of collection. Each specimen type must come with its own test request form and packaged using individual biohazard specimen transport bags. Leaking specimens will be rejected. Specimen transport

conditions must be followed or sample will be rejected. Proper storage and transport conditions preserve analyte integrity within the sample. Samples submitted with incomplete intake information, incomplete patient history, incomplete or discrepant patient sample identifiers and labelling information, or incomplete test request form will not be tested.

- 7. For consultation regarding appropriate testing, provider should contact the Los Angeles County Department of Public Health Acute Communicable Disease Control (ACDC). ACDC can be contacted by calling 213-240-7941 during business hours. After hours, weekends, or holidays contact the County Operator (option 8) and ask for the Public Health Physician on call at 213-974-1234.
- 8. For questions regarding specimen collection or laboratory interpretation, provider should contact the Los Angeles County Public Health Laboratories. The laboratory can be contacted at 562-658-1330 during business hours. After hours, weekends, or holidays contact the County Operator (option 8) and ask for the Public Health Laboratories Director at 213-974-1234.
- 9. Laboratory samples should be sent to:

Los Angeles County Public Health Laboratories 12750 Erickson Avenue Downey, CA 90242 Phone 562-658-1330 Fax 562-401-5999

At this time, laboratory samples for Zika testing should not be sent directly to the California State Department of Public Health or Centers for Disease Control.

If provider does not have access to courier services, the Public Health Laboratories will assist to arrange for sample pick up. Courier arrangements are made by calling Public Health Laboratories Central Accessioning Unit at 562-658-1460.

10. Provider may be required to complete additional forms for receiving results by fax if not currently a client of the Los Angeles County Public Health Laboratories. Note, convalescent serum or an additional serum sample may be requested depending on laboratory results.



#### ZIKA TESTING AND NOTIFICATION

| Indications for Zika testing  | IgM<br>serology <sup>1</sup><br>(serum,<br>CSF) | RT-PCR <sup>2</sup><br>(serum,<br>urine, or<br>other<br>sample<br>types) | Call to Notify<br>Public Health<br>of these<br>special cases<br>213-240-7941 |
|---|---|--|--|
| Pregnancy-associated  |   |  |  |
| Symptomatic pregnant traveler (At least one of the following: acute onset of fever [measured or reported], maculopapular rash, arthralgia, conjunctivitis)  | YES   | YES  | NO   |
| Asymptomatic pregnant traveler  | YES <sup>3</sup>                                | NO   | NO   |
| Pregnant traveler with ultrasound evidence of fetal microcephaly (occipitofrontal circumference <3 <sup>rd</sup> percentile for age and gender) and/or calcifications <sup>4</sup> OR fetal loss <sup>5</sup> | YES   | YES  | YES  |
| Infant with microcephaly and/or calcifications and evidence of maternal Zika virus infection <sup>6</sup>   | YES   | YES <sup>7</sup>   | YES  |
| Infant with no apparent defect and evidence of maternal Zika virus infection <sup>6</sup>   | YES   | YES  | YES  |
| Symptomatic pregnant woman without travel history who had unprotected sex with a symptomatic male traveler from Zika affected area  | YES   | YES  | YES  |
| In Non-Pregnant Patients  |   |  |  |
| Symptomatic non-pregnant traveler (male or female) (At least one of the following: acute onset of fever [measured or reported], maculopapular rash, arthralgia, conjunctivitis)                               | YES   | YES  | NO   |
| Traveler with Guillain-Barré Syndrome diagnosis   | YES   | NO   | YES  |

<sup>&</sup>lt;sup>1</sup> For those symptomatic, collect serum for IgM ≥4 days post symptom onset

<sup>&</sup>lt;sup>2</sup> If ≤7 days from onset of symptoms, **submit both urine and serum specimens**; urine should be collected within 14 days of symptom onset to improve sensitivity of diagnosis, however urine specimens collected within 30 days will continue to be accepted.

<sup>&</sup>lt;sup>3</sup> Collect sample between 2-12 weeks of return

<sup>&</sup>lt;sup>4</sup> Consider testing amniotic fluid

<sup>&</sup>lt;sup>5</sup> Additional specimens will be requested: e.g. placenta, fetal tissues

<sup>&</sup>lt;sup>6</sup> Positive or inconclusive Zika virus serology

<sup>&</sup>lt;sup>7</sup> Additional specimens will be requested: e.g. cord blood, placenta/umbilical cord tissue, CSF



#### SPECIMEN REQUIREMENTS FOR ZIKA TESTING

Clinics able to process specimens may centrifuge blood and transfer serum to a separate, sterile labeled tube. Note, requested sample volumes are for adults. Samples must be sent to the Los Angeles County Public Health Laboratories as soon as possible and within 24 hours of collection.

| Test  | Specimen Type  | Specimen Requirements  | Storage and Transport<br>Conditions*   |  |  |
|---|--|--|--|--|--|
| Zika IgM serology   | Serum  | (QTY 2) 5-7 mL plastic red top or gold top serum separator tube**  | Store at 4-8°C and immediately ship on cold pack   |  |  |
|   | CSF<br>(if collected for<br>other purposes)  | 2 mL collected in sterile container  | Store at 4-8°C and immediately ship on cold pack   |  |  |
| Zika real-time<br>RT-PCR  | Serum  | (QTY 2)<br>5-7 mL plastic red top or gold<br>top serum separator tube**  | Store at 4-8°C and immediately ship on cold pack   |  |  |
| Note: Serum is the primary specimen type for Zika PCR. Other samples may be requested depending on patient status and   | CSF<br>(if collected for<br>other purposes)  | 2 mL collected in sterile container  | Store at 4-8°C and immediately ship on cold pack   |  |  |
|   | Urine, random  | 10-20 mL collected in sterile container  | Store at 4-8°C and immediately ship on cold pack   |  |  |
| history.  | COLLECT THESE SPECIMEN TYPES ONLY UPON CONSULTATION AND INSTRUCTION FROM PUBLIC HEALTH |  |  |  |  |
| If <7 days from onset of symptoms, submit both urine and serum specimens; urine should be collected within 14 days of symptom onset to improve sensitivity of diagnosis, however urine specimens collected within 30 days will continue to be accepted. | Amniotic Fluid   | 5-10 mL collected in sterile container   | Store at 4-8°C and immediately ship on cold pack   |  |  |
|   | Cord Blood   | (QTY 2) 5-7 mL red top or<br>gold top serum separator<br>tube**  | Store at 4-8°C and immediately ship on cold pack   |  |  |
|   | Placenta   | Intact if early gestation or extensive sampling of full thickness pieces including disk, membranes, umbilical cord, any pathologic lesions | Store fresh sample at 4-8°C and immediately ship on cold pack. If frozen, ship on dry ice. If fixed, ship at room temperature. |  |  |
|   | ***Fetal Tissue,<br>fresh or frozen  | At minimum, 1 cm³ section from each organ collected in sterile container   | Store fresh sample at 4-8°C and immediately ship on cold pack. If frozen, ship on dry ice.                                     |  |  |
|   | ***Fetal Tissue,<br>Formalin Fixed   | At minimum,<br>1 cm <sup>3</sup> section   | Store and ship at room temperature   |  |  |
|   | ***Fetal Tissue,<br>Paraffin Block   | Paraffin embedded block  | Store and ship at room temperature   |  |  |
| Zika Histopathology and Immunohistochemistry  | ***Fetal Tissue,<br>Fixed or Paraffin<br>Block   | As above   | Store and ship at room temperature   |  |  |

<sup>\*</sup> Specimens must be received within 24 hours of collection.

<sup>\*\*</sup>Do not use glass vacutainer tube for blood collection. Do not use tubes that contain anti-coagulants.

<sup>\*\*\*</sup>To optimize evaluation of possible Zika virus infection on fetal tissues, please provide both formalin fixed and unfixed tissues. If it is not possible to provide both types of tissues, prioritize formalin fixed tissues. For additional information regarding collection of fetal or infant tissues, please contact the Public Health Laboratories for guidance.